Anti-tumor activity and tolerability of hu14.18-IL2 with GMCSF and isotretinoin in recurrent or refractory neuroblastoma: a Children’s Oncology Group phase II study

PURPOSE: Combining anti-GD2 (disialoganglioside) monoclonal antibody with GM-CSF, IL2 and isotretinoin is now FDA-approved for high-risk neuroblastoma (NB) minimal residual disease (MRD) therapy. The humanized anti-GD2 antibody conjugated to IL2 (hu14.18-IL2) has clinical activity in NB and is more...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Shusterman, Suzanne, Naranjo, Arlene, Van Ryn, Collin, Hank, Jaquelyn A., Parisi, Marguerite T., Shulkin, Barry L., Servaes, Sabah, London, Wendy B., Shimada, Hiroyuki, Gan, Jacek, Gillies, Steven D., Maris, John M., Park, Julie R., Sondel, Paul M.
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6945765/
https://ncbi.nlm.nih.gov/pubmed/31358541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-0798
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars